Skip to search formSkip to main contentSkip to account menu

ZK 222584

Known as: ZK-222584, ZK222584 
National Institutes of Health

Related topics

Related topics

3 relations
PTK 787Vatalanib Succinate

Broader (1)

vatalanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC)
2007
2007
A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK…
14012 Background: The aim of this study was to define the maximum tolerated dose (MTD) for weekly paclitaxel administered in… 
2006
2006
Ionizing Radiation AntagonizesTumor Hypoxia Induced byAntiangiogenic Treatment
Purpose:The combined treatment modality of ionizing radiation with inhibitors of angiogenesis is effective despite the… 
2005
2005
In vivo TargetModulation and Biological Activity of CHIR-258 , aMultitargeted Growth Factor Receptor Kinase Inhibitor , in Colon CancerModels
Purpose:To evaluate the therapeutic and biological effects of CHIR-258, an orally bioavailable, potent inhibitor of class III-V… 
2000
2000
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
The sprouting of new blood vessels, or angiogenesis, is necessary for any solid tumor to grow large enough to cause life… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)